opioid use disorder
Spotlight: Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression (Manza, et al, 2025)
Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. 3-month timepoint - strong treatment adherence with self-reported depression symptoms decrease